Ardelyx (ARDX) $3.40, Receives FDA Approval.
BooYah, Ardelyx shoots and we score (again) last week..but wait, there's more!
It trades down post-approval as short-term...
Is Ardelyx (ARDX) $4.00 Ready to Break Out?
We're up 160% ($579 million) in Ardelyx since adding it to the Watch List about ten months ago in November, but we...
Plansource Invites DarioHealth (DRIO) Into 50 Broker Partnership Network, Serving 5 Million Patients.
This looks like a coup for DarioHealth (DRIO), getting it's digital health solutions in front of more than 5 million new potential...
Adding Dario Health (DRIO) $2.81 to Watch List.
LIVE QUOTE
Adding DarioHealth to Top Stocks of 2023...
With Help of Sanofi (SNY), Dario Health (DRIO) Builds Scientific Case for Its Diabetes...
We always find it Interesting when a Company with a $130 billion market cap (Sanofi: SNY), teams up with a Company...
Tsunami of Business Headed Pressure Bio’s (PBIO) Way?
We think there is a potential Tsunami of business headed towards Pressure Bio over then next 3-5 years. And well beyond....
Report: Is Psycheceutical BioScience (BWVI) One of the Most Important Companies in the Psychedelic...
Initiating Coverage on Psycheceutical BioScience (BWVI).
"Imagine Applying a Psychedelic Topically, Receiving the Benefits...
Hepion Pharmaceuticals (HEPA) Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial...
Completion of Enrollment Remains on Track for Q1, 2024
"While we recently had fireworks, we could be looking at...
Psycheceutical’s (BWVI) NeuroDirect™ Ketamine can Help Alleviate Headaches and Migraines Within Minutes, With no...
Photo MAPS Founder Rick Doblin visits Psycheceutical's Chief Visionary Officer Mike 'Zappy' Zapolin, CEO Chad Harman at the company's lab and tests...
Psycheceutical Bioscience (BWVI) Secures Funding for Clinical Trials
Psycheceutical Secures Funding for Clinical Trials of NeuroDirect™ Ketamine Topical to Treat PTSD.
Company raises $1.3M USD convertible note...
Latest article
Adding Quantum Pharmaceutical (QNTM) $4.10 to Reverse Split Stock Watch List.
119% Gain Post Split
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
